Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/57836
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tavitiya Sudjaritruk | en_US |
dc.contributor.author | Torsak Bunupuradah | en_US |
dc.contributor.author | Linda Aurpibul | en_US |
dc.contributor.author | Pope Kosalaraksa | en_US |
dc.contributor.author | Nia Kurniati | en_US |
dc.contributor.author | Jiratchaya Sophonphan | en_US |
dc.contributor.author | Jintanat Ananworanich | en_US |
dc.contributor.author | Thanyawee Puthanakit | en_US |
dc.date.accessioned | 2018-09-05T03:50:41Z | - |
dc.date.available | 2018-09-05T03:50:41Z | - |
dc.date.issued | 2017-01-01 | en_US |
dc.identifier.issn | 20402058 | en_US |
dc.identifier.issn | 13596535 | en_US |
dc.identifier.other | 2-s2.0-85037044596 | en_US |
dc.identifier.other | 10.3851/IMP3103 | en_US |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85037044596&origin=inward | en_US |
dc.identifier.uri | http://cmuir.cmu.ac.th/jspui/handle/6653943832/57836 | - |
dc.description.abstract | © 2017 International Medical Press. Background: This study aimed to determine the effect of tenofovir disoproxil fumarate (TDF) on bone metabolism and bone mass in HIV-infected adolescents. Methods: This was a sub-study of a cross-sectional multicentre bone health trial that enrolled perinatally HIV-infected Thai and Indonesian adolescents (10–18 years) with viral suppression on antiretroviral therapy. Participants were classified into two groups as TDF users and non-users. Bone metabolism-related markers (25-hydroxyvitamin D [25-OHD], intact parathyroid hormone [iPTH], bone turnover biomarkers), and lumbar spine dual-energy X-ray absorptiometry were assessed. Bone mineral density (BMD)/bone mineral apparent density (BMAD) Z-scores were calculated. Results: Of 394 adolescents, 136 (34.5%) and 258 (65.5%) were TDF users and non-users, respectively. Among TDF users, median age (IQR) was 16.1 (14.7–17.4) years and TDF treatment duration (IQR) was 2.3 (1.4–3.1) years. Among TDF non-users, median age (IQR) was 14.3 (12.6–16.4) years. BMD and BMAD Z-scores comparing TDF users with non-users were -0.8 and -0.6 (P=0.27), and -0.3 and -0.2 (P=0.58), respectively. The association between TDF use and iPTH elevation was intensified in adolescents with suboptimal vitamin D levels (25-OHD <30 ng/ml; P=0.001). TDF administration was positively associated with bone resorption marker (P=0.04) and negatively associated with bone formation marker (P=0.04). With data up to 4 years, neither association between TDF use and bone mass loss (BMD: P=0.09; BMAD: P=0.22), nor variation of bone mass Z-scores by TDF treatment duration (BMD: P=0.34; BMAD: P=0.58) was demonstrated. Conclusions: Recent TDF administration was correlated with PTH elevation and bone turnover dysregulation but not with bone mass reduction in our cohort. A study with extended follow-up to ascertain TDF-associated bone mass deterioration is warranted. | en_US |
dc.subject | Medicine | en_US |
dc.subject | Pharmacology, Toxicology and Pharmaceutics | en_US |
dc.title | Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents | en_US |
dc.type | Journal | en_US |
article.title.sourcetitle | Antiviral Therapy | en_US |
article.volume | 22 | en_US |
article.stream.affiliations | Chiang Mai University | en_US |
article.stream.affiliations | The HIV Netherlands Australia Thailand Research Collaboration | en_US |
article.stream.affiliations | Khon Kaen University | en_US |
article.stream.affiliations | University of Indonesia, RSUPN Dr. Cipto Mangunkusumo | en_US |
article.stream.affiliations | HJF | en_US |
article.stream.affiliations | Chulalongkorn University | en_US |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.